From: BuyandBill.com <info@buyandbill.com>
To: [customer]
Subject: J1932, Lanreotide Injection (Cipla) has received Pass-Through Status G from The Centers for Medicare and Medicaid (CMS)
Effective January 1, 2023:
J1932, injection, lanreotide, (Cipla), has received Pass-Through Status G from
The Centers for Medicare and Medicaid (CMS)1
HCPCS
Code
HCPCS Code
Descriptor
NDC
Number
How
Supplied
APC Per HCPCS Unit (1 mg)
HCPCS Units Per Package
J1932
injection, lanreotide, (Cipla), 1 mg
69097-0870-67
Lanreotide Acetate Subcutaneous Solution 120/MG/.05mL
$60.378
120
Please contact us @ Account.Management@Cipla.com
© Copyright 2023 Cipla USA Inc. All rights reserved
January 2023 CUSAI-09292022-01
References: 1. https://www.cms.gov/license/ama?file=/files/zip/january-2023-opps-addendum-b.zip